Pulmonary Disease Doctors in Bayside, NY Accepting Medicare

2 Pulmonary Disease doctors found. Showing 1 - 2

Theo Trandafirescu, Internal Medicine - Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 216 -16 Union Tpke, Bayside, NY 11367 Phone: 718-465-4000    Fax: 718-776-6823

Jack Michael Mann, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 42-23 Francis Lewis Blvd., Ste. 105, Bayside, NY 11361 Phone: 718-225-5106    Fax: 718-225-0816

News Archive

Small fraction of film and television productions provide complete, accurate information on brain death

Neurologists who examined how brain death and organ donation are portrayed in film and television found that only a small fraction of productions provide the public with a complete and accurate understanding of brain death.

Occupational exposure to pesticides increases risk for cardiovascular disease among Latinos

Latinos who are exposed to pesticides in their workplaces are twice as likely to have cardiovascular disease compared with Latinos who are not exposed to pesticides at work, according to a new study published in the journal Heart.

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July 22, 2014.

Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.

Read more Medical News

› Verified 5 days ago